Authors: van Veen, T Crusius, JBA Schrijver, HM Bouma, G Killestein, J van Winsen, L Pena, AS Polman, CH Uitdehaag, BMJ

Citation: T. Van Veen et al., Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis, ANN NEUROL, 50(2), 2001, pp. 275-275

Authors: de Jong, BA Schrijver, HM Huizinga, TWJ Bollen, ELEM Polman, CH Uitdehaag, BMJ Kersbergen, MC Sturk, A Westendorp, RGJ

Citation: Ba. De Jong et al., Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis, ANN NEUROL, 48(4), 2000, pp. 641-646

Authors: van Boxel-Dezaire, AHH van Trigt-Hoff, SCJ Killestein, J Schrijver, HM van Houwelingen, JC Polman, CH Nagelkerken, L

Citation: Ahh. Van Boxel-dezaire et al., Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?, ANN NEUROL, 48(3), 2000, pp. 313-322

Authors: Killestein, J Schrijver, HM Crusius, JBA Perez, C Uitdehaag, BMJ Pena, AS Polman, CH

Citation: J. Killestein et al., Intracellular adhesion molecule-1 polymorphisms and genetic susceptibilityto multiple sclerosis: Additional data and meta-analysis, ANN NEUROL, 47(2), 2000, pp. 277-278

Authors: Rep, MHG Schrijver, HM van Lopik, T Hintzen, RQ Roos, MTL Ader, HJ Polman, CH van Lier, RAW

Citation: Mhg. Rep et al., Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients, J NEUROIMM, 96(1), 1999, pp. 92-100

Authors: Schrijver, HM Crusius, JBA Uitdehaag, BMJ Gonzalez, MAG Kostense, PJ Polman, CH Pena, AS

Citation: Hm. Schrijver et al., Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS, NEUROLOGY, 52(3), 1999, pp. 595-599